-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pharm.
com, May 31, on May 27, the official website of the State Food and Drug Administration showed that Shanghai Shangyao Zhongxi Pharmaceutical’s duloxetine hydrochloride enteric-coated tablets was approved as a supplementary application, and it was the first company to have reviewed the product.
.
According to data from Meinenet, the sales of terminal duloxetine tablets in China's public medical institutions will exceed 500 million yuan in 2020, a year-on-year increase of 13.
27%.
There are only two manufacturers of duloxetine hydrochloride enteric-coated tablets, of which Shanghai Shangyao Zhongxi Pharmaceutical has the largest market share.
com, May 31, on May 27, the official website of the State Food and Drug Administration showed that Shanghai Shangyao Zhongxi Pharmaceutical’s duloxetine hydrochloride enteric-coated tablets was approved as a supplementary application, and it was the first company to have reviewed the product.
.
According to data from Meinenet, the sales of terminal duloxetine tablets in China's public medical institutions will exceed 500 million yuan in 2020, a year-on-year increase of 13.
27%.
There are only two manufacturers of duloxetine hydrochloride enteric-coated tablets, of which Shanghai Shangyao Zhongxi Pharmaceutical has the largest market share.
May 27, 2021 release of drug approval documents pending receipt
Duloxetine is a selective serotonin (5-HT) and norepinephrine (NE) reuptake dual inhibitor.
It exerts antidepressant effect by inhibiting the reuptake of 5-HT and NE.
It is mainly used clinically.
For the treatment of depression and generalized anxiety disorder.
It exerts antidepressant effect by inhibiting the reuptake of 5-HT and NE.
It is mainly used clinically.
For the treatment of depression and generalized anxiety disorder.
Sales of terminal duloxetine tablets in Chinese public medical institutions in recent years
Source: Terminal competition landscape of China's public medical institutions
According to data from Meinnet.
com, in recent years , the sales of terminal duloxetine tablets in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly, exceeding 500 million yuan in 2020, a year-on-year increase.
An increase of 13.
27%.
com, in recent years , the sales of terminal duloxetine tablets in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly, exceeding 500 million yuan in 2020, a year-on-year increase.
An increase of 13.
27%.
Source: One-click search on Mi Nei.
com
com
Duloxetine with film production companies have on the Shanghai and Jiangsu En Hua Pharmaceutical medicine and Western medicine two, which, Shanghai's largest pharmaceutical market share of Chinese and Western medicine.
Prior to this, no company has been approved for duloxetine hydrochloride enteric-coated tablets, and only the supplementary application for the consistency evaluation of Shanghai Shanghai Pharmaceuticals Chinese and Western Pharmaceuticals is under review.
Prior to this, no company has been approved for duloxetine hydrochloride enteric-coated tablets, and only the supplementary application for the consistency evaluation of Shanghai Shanghai Pharmaceuticals Chinese and Western Pharmaceuticals is under review.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
Pharm.
com, May 31, on May 27, the official website of the State Food and Drug Administration showed that Shanghai Shangyao Zhongxi Pharmaceutical’s duloxetine hydrochloride enteric-coated tablets was approved as a supplementary application, and it was the first company to have reviewed the product.
.
According to data from Meinenet, the sales of terminal duloxetine tablets in China's public medical institutions will exceed 500 million yuan in 2020, a year-on-year increase of 13.
27%.
There are only two manufacturers of duloxetine hydrochloride enteric-coated tablets, of which Shanghai Shangyao Zhongxi Pharmaceutical has the largest market share.
com, May 31, on May 27, the official website of the State Food and Drug Administration showed that Shanghai Shangyao Zhongxi Pharmaceutical’s duloxetine hydrochloride enteric-coated tablets was approved as a supplementary application, and it was the first company to have reviewed the product.
.
According to data from Meinenet, the sales of terminal duloxetine tablets in China's public medical institutions will exceed 500 million yuan in 2020, a year-on-year increase of 13.
27%.
There are only two manufacturers of duloxetine hydrochloride enteric-coated tablets, of which Shanghai Shangyao Zhongxi Pharmaceutical has the largest market share.
May 27, 2021 release of drug approval documents pending receipt
Duloxetine is a selective serotonin (5-HT) and norepinephrine (NE) reuptake dual inhibitor.
It exerts antidepressant effect by inhibiting the reuptake of 5-HT and NE.
It is mainly used clinically.
For the treatment of depression and generalized anxiety disorder.
It exerts antidepressant effect by inhibiting the reuptake of 5-HT and NE.
It is mainly used clinically.
For the treatment of depression and generalized anxiety disorder.
Sales of terminal duloxetine tablets in Chinese public medical institutions in recent years
Source: Terminal competition landscape of China's public medical institutions
According to data from Meinnet.
com, in recent years , the sales of terminal duloxetine tablets in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly, exceeding 500 million yuan in 2020, a year-on-year increase.
An increase of 13.
27%.
com, in recent years , the sales of terminal duloxetine tablets in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly, exceeding 500 million yuan in 2020, a year-on-year increase.
An increase of 13.
27%.
Source: One-click search on Mi Nei.
com
com
Duloxetine with film production companies have on the Shanghai and Jiangsu En Hua Pharmaceutical medicine and Western medicine two, which, Shanghai's largest pharmaceutical market share of Chinese and Western medicine.
Prior to this, no company has been approved for duloxetine hydrochloride enteric-coated tablets, and only the supplementary application for the consistency evaluation of Shanghai Shanghai Pharmaceuticals Chinese and Western Pharmaceuticals is under review.
Prior to this, no company has been approved for duloxetine hydrochloride enteric-coated tablets, and only the supplementary application for the consistency evaluation of Shanghai Shanghai Pharmaceuticals Chinese and Western Pharmaceuticals is under review.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
Pharm.
com, May 31, on May 27, the official website of the State Food and Drug Administration showed that Shanghai Shangyao Zhongxi Pharmaceutical’s duloxetine hydrochloride enteric-coated tablets was approved as a supplementary application, and it was the first company to have reviewed the product.
.
According to data from Meinenet, the sales of terminal duloxetine tablets in China's public medical institutions will exceed 500 million yuan in 2020, a year-on-year increase of 13.
27%.
There are only two manufacturers of duloxetine hydrochloride enteric-coated tablets, of which Shanghai Shangyao Zhongxi Pharmaceutical has the largest market share.
com, May 31, on May 27, the official website of the State Food and Drug Administration showed that Shanghai Shangyao Zhongxi Pharmaceutical’s duloxetine hydrochloride enteric-coated tablets was approved as a supplementary application, and it was the first company to have reviewed the product.
.
According to data from Meinenet, the sales of terminal duloxetine tablets in China's public medical institutions will exceed 500 million yuan in 2020, a year-on-year increase of 13.
27%.
There are only two manufacturers of duloxetine hydrochloride enteric-coated tablets, of which Shanghai Shangyao Zhongxi Pharmaceutical has the largest market share.
May 27, 2021 release of drug approval documents pending receipt
Duloxetine is a selective serotonin (5-HT) and norepinephrine (NE) reuptake dual inhibitor.
It exerts antidepressant effect by inhibiting the reuptake of 5-HT and NE.
It is mainly used clinically.
For the treatment of depression and generalized anxiety disorder.
It exerts antidepressant effect by inhibiting the reuptake of 5-HT and NE.
It is mainly used clinically.
For the treatment of depression and generalized anxiety disorder.
Sales of terminal duloxetine tablets in Chinese public medical institutions in recent years
Source: Terminal competition landscape of China's public medical institutions
According to data from Meinnet.
com, in recent years , the sales of terminal duloxetine tablets in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly, exceeding 500 million yuan in 2020, a year-on-year increase.
An increase of 13.
27%.
Hospital hospital hospitalcom, in recent years , the sales of terminal duloxetine tablets in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly, exceeding 500 million yuan in 2020, a year-on-year increase.
An increase of 13.
27%.
Source: One-click search on Mi Nei.
com
com
Duloxetine with film production companies have on the Shanghai and Jiangsu En Hua Pharmaceutical medicine and Western medicine two, which, Shanghai's largest pharmaceutical market share of Chinese and Western medicine.
Prior to this, no company has been approved for duloxetine hydrochloride enteric-coated tablets, and only the supplementary application for the consistency evaluation of Shanghai Shanghai Pharmaceuticals Chinese and Western Pharmaceuticals is under review.
Enterprise business enterprisePrior to this, no company has been approved for duloxetine hydrochloride enteric-coated tablets, and only the supplementary application for the consistency evaluation of Shanghai Shanghai Pharmaceuticals Chinese and Western Pharmaceuticals is under review.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
